Opgen Inc - Understand $opgn stock

$OPGN Market Cap: $16.11 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.266M

TTM

Gross Margin

23.17%

TTM

Net Earnings

-$9.301M

TTM

Current Assets

$3.217M

Q3 2024

Current Liabilities

$589.8K

Q3 2024

Current Ratio

545.53%

Q3 2024

Total Assets

$5.470M

Q3 2024

Total Liabilities

$2.484M

Q3 2024

Book Value

$2.986M

Q3 2024

Cash

$1.633M

Q3 2024

P/E

-1.732

Nov 29, 2024 EST

Free Cash Flow

-$2.761M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$3.418M	$2.607M	$4.306M	$4.214M	$3.499M	$2.946M	$3.211M	$4.026M	$3.158M	$4.126M	$2.410M	$5.800M
YoY Change	31.11%	-39.45%	2.17%	20.46%	18.75%	-8.24%	-20.24%	27.49%	-23.47%	71.22%	-58.45%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$3.418M	$2.607M	$4.306M	$4.214M	$3.499M	$2.946M	$3.211M	$4.026M	$3.158M	$4.126M	$2.410M	$5.800M
Cost Of Revenue	$3.084M	$3.320M	$2.848M	$3.850M	$1.630M	$1.850M	$520.3K	$631.3K	$367.8K	$526.2K	$1.820M	$3.210M
Gross Profit	$334.2K	-$712.3K	$1.458M	$370.0K	$1.870M	$1.100M	$2.691M	$3.394M	$2.790M	$3.600M	$590.0K	$2.590M
Gross Profit Margin	9.78%	-27.32%	33.85%	8.78%	53.45%	37.33%	83.8%	84.32%	88.35%	87.25%	24.48%	44.66%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$10.86M	$13.23M	$13.65M	$11.90M	$7.720M	$8.601M	$9.460M	$12.13M	$10.14M	$4.371M	$5.820M	$6.750M
YoY Change	-17.87%	-3.08%	14.74%	54.09%	-10.24%	-9.08%	-22.02%	19.64%	131.98%	-24.9%	-13.78%
% of Gross Profit	3250.59%		936.43%	3215.07%	412.83%	781.9%	351.6%	357.41%	363.45%	121.41%	986.44%	260.62%
Research & Development	$4.733M	$8.173M	$10.91M	$9.965M	$5.120M	$5.677M	$6.883M	$8.613M	$6.003M	$4.368M	$4.150M	$4.780M
YoY Change	-42.09%	-25.09%	9.49%	94.62%	-9.82%	-17.52%	-20.08%	43.48%	37.42%	5.26%	-13.18%
% of Gross Profit	1415.98%		748.55%	2693.17%	273.8%	516.11%	255.82%	253.75%	215.17%	121.34%	703.39%	184.56%
Depreciation & Amortization	$1.319M	$1.643M	$2.714M	$2.335M	$921.4K	$730.9K	$669.1K	$656.0K	$624.7K	$573.9K	$660.0K	$580.0K
YoY Change	-19.73%	-39.47%	16.24%	153.4%	26.06%	9.24%	1.99%	5.03%	8.84%	-13.04%	13.79%
% of Gross Profit	394.5%		186.19%	631.01%	49.27%	66.44%	24.87%	19.33%	22.39%	15.94%	111.86%	22.39%
Operating Expenses	$15.60M	$21.40M	$24.56M	$21.86M	$12.84M	$14.28M	$16.34M	$20.75M	$18.22M	$9.691M	$9.970M	$11.53M
YoY Change	-27.12%	-12.86%	12.35%	70.25%	-10.07%	-12.64%	-21.22%	13.88%	87.98%	-2.8%	-13.53%
Operating Profit	-$30.75M	-$34.57M	-$23.27M	-$22.72M	-$12.27M	-$13.18M	-$15.27M	-$19.01M	-$15.06M	-$5.565M	-$9.380M	-$8.940M
YoY Change	-11.05%	48.53%	2.44%	85.14%	-6.9%	-13.66%	-19.69%	26.23%	170.62%	-40.68%	4.92%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$1.839M	$3.256M	$4.799M	$3.399M	$187.5K	$191.2K	$233.5K	$143.3K	$1.801M	$111.3K	$100.0K	-$110.0K
YoY Change	-43.53%	-32.15%	41.18%	1712.53%	-1.91%	-18.12%	62.89%	-92.04%	1517.78%	11.35%	-190.91%
% of Operating Profit
Other Income/Expense, Net	-$1.920M	-$2.716M	-$11.49M	-$3.360M	-$175.2K	-$187.9K	-$153.5K	-$157.4K	-$2.422M	-$106.8K	$90.00K	-$230.0K
YoY Change	-29.32%	-76.36%	241.93%	1817.64%	-6.73%	22.37%	-2.48%	-93.5%	2168.03%	-218.65%	-139.13%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$32.67M	-$37.28M	-$34.76M	-$26.08M	-$12.45M	-$13.37M	-$15.42M	-$19.17M	-$17.48M	-$5.671M	-$10.13M	-$9.280M
YoY Change	-12.38%	7.25%	33.3%	109.52%	-6.89%	-13.3%	-19.55%	9.64%	208.23%	-44.01%	9.16%
Income Tax			$43.83K	$132.4K	$0.00	$0.00	$0.00	$0.00	-$129.1K	$0.00
% Of Pretax Income
Net Earnings	-$32.67M	-$37.28M	-$34.81M	-$26.21M	-$12.45M	-$13.37M	-$15.42M	-$19.17M	-$17.35M	-$5.671M	-$10.13M	-$9.280M
YoY Change	-12.38%	7.12%	32.79%	110.59%	-6.89%	-13.3%	-19.55%	10.46%	205.95%	-44.01%	9.16%
Net Earnings / Revenue	-955.69%	-1429.96%	-808.3%	-621.93%	-355.75%	-453.72%	-480.2%	-476.11%	-549.51%	-137.44%	-420.33%	-160.0%
Basic Earnings Per Share	-$41.47	-$15.27	-$22.89
Diluted Earnings Per Share	-$41.47	-$15.27	-$949.1K	-$1.659M	-$7.685M	-$44.57M	-$192.8M	-$479.3M	-$578.3M	-$283.5M	-$506.5M	-$464.0M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$1.152M	$7.440M	$36.08M	$13.36M	$2.710M	$4.570M	$1.850M	$4.120M	$7.810M	$750.0K	$1.400M	$7.120M
YoY Change	-84.52%	-79.38%	170.06%	392.99%	-40.7%	147.03%	-55.1%	-47.25%	941.33%	-46.43%	-80.34%
Cash & Equivalents	$1.152M	$7.440M	$36.08M	$13.36M	$2.710M	$4.570M	$1.850M	$4.120M	$7.810M	$750.0K	$1.400M	$7.120M
Short-Term Investments
Other Short-Term Assets	$324.7K	$1.356M	$1.250M	$1.390M	$400.0K	$290.0K	$310.0K	$330.0K	$570.0K	$90.00K	$150.0K	$290.0K
YoY Change	-76.05%	8.45%	-10.05%	247.5%	37.93%	-6.45%	-6.06%	-42.11%	533.33%	-40.0%	-48.28%
Inventory	$0.00	$1.345M	$1.239M	$1.490M	$470.0K	$540.0K	$530.0K	$690.0K	$830.0K	$370.0K	$180.0K	$910.0K
Prepaid Expenses
Receivables	$103.3K	$514.4K	$1.172M	$650.0K	$570.0K	$370.0K	$810.0K	$540.0K	$680.0K	$500.0K	$240.0K	$1.140M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$2.520M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.580M	$10.66M	$39.74M	$16.89M	$6.670M	$5.780M	$3.500M	$5.680M	$9.890M	$1.710M	$1.960M	$9.460M
YoY Change	-85.17%	-73.19%	135.3%	153.22%	15.4%	65.14%	-38.38%	-42.57%	478.36%	-12.76%	-79.28%
Property, Plant & Equipment	$140.00	$4.920M	$5.917M	$5.790M	$2.130M	$1.220M	$840.0K	$800.0K	$1.070M	$590.0K	$1.080M	$890.0K
YoY Change	-100.0%	-16.84%	2.19%	171.83%	74.59%	45.24%	5.0%	-25.23%	81.36%	-45.37%	21.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$302.3K	$2.796M	$4.024M	$2.470M	$200.0K	$260.0K	$330.0K	$280.0K	$270.0K	$350.0K	$60.00K	$80.00K
YoY Change	-89.19%	-30.51%	62.92%	1135.0%	-23.08%	-21.21%	17.86%	3.7%	-22.86%	483.33%	-25.0%
Total Long-Term Assets	$302.4K	$15.16M	$31.92M	$32.86M	$3.750M	$3.170M	$3.120M	$3.300M	$3.870M	$940.0K	$1.200M	$1.140M
YoY Change	-98.0%	-52.52%	-2.85%	776.27%	18.3%	1.6%	-5.45%	-14.73%	311.7%	-21.67%	5.26%
Total Assets	$1.882M	$25.81M	$71.67M	$49.75M	$10.42M	$8.950M	$6.620M	$8.980M	$13.76M	$2.650M	$3.160M	$10.60M
YoY Change
Accounts Payable	$111.2K	$420.8K	$1.307M	$1.870M	$1.060M	$1.620M	$1.690M	$2.230M	$2.290M	$1.160M	$870.0K	$600.0K
YoY Change	-73.59%	-67.8%	-30.1%	76.42%	-34.57%	-4.14%	-24.22%	-2.62%	97.41%	33.33%	45.0%
Accrued Expenses	$411.0K	$3.001M	$4.047M	$4.530M	$2.920M	$1.940M	$1.910M	$1.790M	$2.000M	$1.420M	$1.260M	$1.380M
YoY Change	-86.31%	-25.84%	-10.65%	55.14%	50.52%	1.57%	6.7%	-10.5%	40.85%	12.7%	-8.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.010M	$1.020M	$0.00	$3.000M	$0.00	$0.00
YoY Change						-100.0%	-0.98%		-100.0%
Long-Term Debt Due	$10.87M	$7.027M	$14.56M	$970.0K	$950.0K	$800.0K	$150.0K	$180.0K	$250.0K	$110.0K	$120.0K	$140.0K
YoY Change	54.74%	-51.74%	1401.26%	2.11%	18.75%	433.33%	-16.67%	-28.0%	127.27%	-8.33%	-14.29%
Total Short-Term Liabilities	$11.42M	$10.59M	$19.92M	$7.370M	$4.940M	$4.380M	$4.790M	$5.270M	$4.590M	$6.020M	$2.760M	$2.270M
YoY Change	7.84%	-46.82%	170.24%	49.19%	12.79%	-8.56%	-9.11%	14.81%	-23.75%	118.12%	21.59%
Long-Term Debt	$0.00	$4.851M	$7.180M	$19.43M	$640.0K	$1.100M	$130.0K	$150.0K	$1.320M	$130.0K	$230.0K	$40.00K
YoY Change	-100.0%	-32.44%	-63.05%	2935.94%	-41.82%	746.15%	-13.33%	-88.64%	915.38%	-43.48%	475.0%
Other Long-Term Liabilities	$2.022M	$2.795M	$3.353M	$1.760M	$550.0K	$160.0K	$300.0K	$400.0K	$350.0K			$130.0K
YoY Change	-27.67%	-16.64%	90.5%	220.0%	243.75%	-46.67%	-25.0%	14.29%
Total Long-Term Liabilities	$2.022M	$7.646M	$10.53M	$21.19M	$1.190M	$1.260M	$430.0K	$550.0K	$1.670M	$130.0K	$230.0K	$170.0K
YoY Change	-73.56%	-27.41%	-50.29%	1680.67%	-5.56%	193.02%	-21.82%	-67.07%	1184.62%	-43.48%	35.29%
Total Liabilities	$13.44M	$18.24M	$30.45M	$28.56M	$6.130M	$5.640M	$5.220M	$5.820M	$6.270M	$6.160M	$2.990M	$2.450M
YoY Change	-26.28%	-40.11%	6.62%	365.91%	8.69%	8.05%	-10.31%	-7.18%	1.79%	106.02%	22.04%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	787.8K shares	2.442M shares	1.834M shares
Diluted Shares Outstanding	787.8K shares	2.442M shares	1.834M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $16.109 Million

About OPGEN INC

OpGen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland. The company went IPO on 2015-05-05. OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The firm distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firm's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.

Industry: Services-Medical Laboratories Peers: Aileron Therapeutics, Inc. APPLIED GENETIC TECHNOLOGIES CORP Inhibitor Therapeutics, Inc. ENZON PHARMACEUTICALS, INC. Indaptus Therapeutics, Inc. Metacrine, Inc. Monopar Therapeutics ONCOSEC MEDICAL Inc